Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. The European respiratory journal, 39(1), 172–179.
https://doi.org/10.1183/09031936.00201210Depuis sa création, l’Institut Roche a mis son expertise au profit de nombreuses publications scientifiques.
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. The European respiratory journal, 39(1), 172–179.
https://doi.org/10.1183/09031936.00201210
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 22(3), 575–581.
https://doi.org/10.1093/annonc/mdq407Résultats :110/110